Start the conversation
When most investors think of legal marijuana, they don't think of high tech or the life sciences.
We have a very different point of view.
Indeed, I've been following this field for many years because of my interest in how cannabinoids derived from marijuana can be used to treat all sorts of ailments – from cancer to arthritis to insomnia.
Plus, this whole field fits into my expertise in what you could call "frontier investing."
By that I mean, you can score massive gains in tech-related sectors by getting in just before it hits the tipping point – when it's still on the "frontier" – and goes mainstream.
Need an example? One cannabis stock I've been watching catapulted more than 170% in just the past six months.
Today, we're going to investigate why this cannabis-focused biotech stock took off like a rocket ship.
We'll also take a look at the big gains investors made in two other stocks.
And I'll show why there's still plenty more money to be made.
It's easy for me to say I'm an expert in "frontier investing."
It's harder to prove it.
But I can.
Let's start with the special report I put out in May 2010 about a group of rare-earth firms.
At the time, no one on Wall Street or in the mainstream media was talking about how badly we need these compounds for everything from missile guidance systems and smartphones to solar cells.
But just six months later, the world woke up to the story of these critical resources. I had my readers take profits on half of their position with combined gains of 350%.
Of course, this kind of special opportunity doesn't come along every day. When it does, however, you can pile up huge profits.
That was clearly the case when I began talking about how big Bitcoin was going to become back in early 2013. At the time, the encrypted digital currency was trading for roughly $100.
By the end of the year, the price had topped $1,200 – for a 1,100% gain in just a few months.
I believe something similar is happening right now as the drive toward legalizing marijuana gains steam not just in the United States, but all over the world.
As I said, my interest comes from the science side. I've read many reports on how you can take active agents out of marijuana – those cannabinoids I mentioned earlier – and create powerful drugs, without the intoxicating effects.
Don't scoff. Though federal law still makes cannabis an illegal substance, even the U.S. National Cancer Institute says cannabinoids "may relieve pain, lower inflammation, and decrease anxiety" without causing users to get high.
No wonder Ackrell Capital predicts that between 2016 and 2029, the market for marijuana will reach $100 billion – 1,308% growth.
Then again, the drive to make cannabis legal at the state level is quickly gaining ground.…
About the Author
Michael A. Robinson is one of the top financial analysts working today. His book "Overdrawn: The Bailout of American Savings" was a prescient look at the anatomy of the nation's S&L crisis, long before the word "bailout" became part of our daily lexicon. He's a Pulitzer Prize-nominated writer and reporter, lauded by the Columbia Journalism Review for his aggressive style. His 30-year track record as a leading tech analyst has garnered him rave reviews, too. Today he is the editor of the monthly tech investing newsletter Nova-X Report as well as Radical Technology Profits, where he covers truly radical technologies – ones that have the power to sweep across the globe and change the very fabric of our lives – and profit opportunities they give rise to. He also explores "what's next" in the tech investing world at Strategic Tech Investor.